bamlanivimab/etesevimab and REGN-COV (casirivimab/imdevimab) – Emergency use authorization revision
January 24, 2022 - The FDA revised the emergency use authorizations (EUAs) for Eli Lilly’s bamlanivimab/etesevimab and Regeneron’s REGEN-COV (casirivimab/imdevimab), limiting their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments.
Top